58791-45-0

Usage

InChI:InChI=1/C16H10O4/c17-15(18)11-5-6-12(16(19)20)14-8-10-4-2-1-3-9(10)7-13(11)14/h1-8H,(H,17,18)(H,19,20)

Upstream product

• 54292-11-4 9,10-dioxo-9,10-dihydro-1,4-anthracene dicarboxylic acid 
• 1519-36-4 1,4-dimethylanthraquinone 
• 7664-41-7 ammonia 

Downstream Products

• 58791-46-1 1,4-Anthracendicarbonsaeure-dimethylester 

Relevant academic research and scientific papers

1,4-disubstituted anthracene antitumor agents

Three different types of 1,4-disubstituted anthracenes were synthesized, and their cytotoxicity in a panel of tumor cells was compared with that of the corresponding 9,10-disubstituted anthracenes. The panel contained human myeloma, melanoma, colon, and lung cancer cells and sensitive and multidrug- resistant murine L1210 leukemia cells. These compounds had [[(dimethylamino)ethyl]amino]methyl, N-[(dimethylamino)ethyl]carbamoyl, and carboxaldehyde (4,5-dihydro-1H-imidazol-2-yl)hydrazone side chains. The 1,4- diamide was more potent across the tumor panel than the corresponding 9,10- isomer, but the 1,4-diamine and the 1,4-hydrazone were less potent than their 9,10-isomers. Although the 1,4-hydrazone was active against P388 leukemia in mice, it was inactive against L1210 leukemia. Within each pair of compounds, the one with greater average potency against tumor cells gave a greater increase in the transition melt temperature of DNA.

Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues

New bisantrene analogues were synthesized, bearing one or two 4,5-dihydro-1H-imidazol-2-yl hydrazone side chains at positions 1,4 or 9 of the anthracene ring system. A 10-aza-bioisostere was also prepared. The position of substituents in structurally isomeric drugs modulates topoisomerase II poisoning and specificity, along with cytotoxicity.

Process for the manufacture of 1,4-disubstituted bicyclic or tricyclic compounds and new 1,4-disubstituted bicyclic compounds

The present invention provides a new process for the manufacture of 1,4-disubstituted bicyclic or tricyclic compounds by reacting a 1,2-bis-cyanomethyl-benzene or 2,3-bis-cyanomethyl-naphthalene with glyoxal in the presence of a base and a solvent as well as new 1,4-disubstituted bicyclic compounds.